Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
57
resultados
Última actualización
09/05/2025 [06:45:00]
Resumen de: EP4549555A2
Chimeric antigen receptors for use in treating lymphoma-associated C-C chemokine receptor type 4 (CCR4) and other cancers expressing CCR4 are described.
Resumen de: US2025137065A1
The present disclosure provides methods of treating lymphoma comprising administering a bispecific CD20×CD3 antibody to a patient in need thereof, wherein the patient is selected on the basis of exhibiting a modified level of circulating tumor (ct) DNA. In certain embodiments, the present disclosure provides methods of identifying a patient with lymphoma who is likely to respond favorably to therapy comprising a bispecific CD20×CD3 antibody.
Resumen de: WO2025088223A2
The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.
Resumen de: WO2025087879A2
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in non-malignant tissues. This obstacle can be minimized by targeting cancer dependencies driven by proteins with tissue- and/or tumor-restricted expression. Here, the inventors show that in acute myeloid leukemia (AML), suppression of the myeloid-restricted PIK3CG/p110γ-PIK3R5/p101 axis blocks AKT signaling, compromises cell fitness, and sensitizes to established AML therapies. Importantly, the inventors find that existing small molecule inhibitors against PIK3CG are insufficient to achieve a sustained longterm anti-leukemic effect. To address this concern, the inventors developed a proteolysis- targeting chimera (PROTAC) heterobifunctional molecule that specifically degrades PIK3CG and potently suppresses AML progression alone and in combination with venetoclax in human AML cell lines, primary AML patient samples, and syngeneic mouse models.
Resumen de: AU2023367741A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025138013A1
Disclosed a method of identifying high-risk Acute Myeloid Leukemia patients based upon the expression of a leukemic stem-cell (LSC) associated gene known as Serine Protease Inhibitor Kazal type 2 (SPINK2), the method including: (i) Immunohistochemistry (IHC)-based detection of SPINK2 protein expression, (ii) quantification of SPINK2 expression using a scoring system (range 0-16), whereby high SPINK2 is defined as a score>3 and (iii) utilization of the score to classify patients as high-risk (score>3) or low risk (score 0-3). Additionally, disclosed is a method of treating AML using a small molecule inhibitor (SMI) that selectively targets a domain of SPINK2 protein in leukemic cells highly expressing SPINK2; wherein the SMI reduces SPINK2 protein expression, alters SPINK2 target gene mRNA expression, inhibits SPINK2 function and consequently LSC proliferation/survival. A method of identifying potential candidates for SPINK2-SMI therapy to enhance treatment outcomes, whereby potential candidates refer to patients with high SPINK2 expression, is also disclosed.
Resumen de: US2025136592A1
Compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are disclosed. Methods for treating acute leukemias using the compounds of Formula I and pharmaceutical compositions comprising the same are also disclosed.
Resumen de: WO2025087936A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: WO2025088065A1
The present invention relates to the field of diagnostics and therapeutics against leukemia. More specifically, it relates to a method for assessing acute myeloid leukemia (AML) in a subject suspected to suffer therefrom comprising the steps of determining in a sample of said subject the amount of at least one biomarker selected from the group consisting of: CLEC7A, CLEC9A, HCST, LST1, LTB, IFITM3, CD74, HLA-DRA, CD164, CD52, CD34, HSPA5, MGST1, CD47, TFPI, IGHM, SELL, CD82, CD69, NDFIP1, RALA, RAB11A, SELENOK, HLA- DRB5, RAMP1, IGLL1, HLA-DQA1, CD96, SLC5A3, VAMPS, CALCRL, LPAR6, NINJ1, CD7, SLC2A5, EREG, FCMR, DLK1, and J AML,, comparing the said amount of the at least one biomarker to a reference, and assessing AML based on the comparison. Yet, the present invention relates to a method for generating a bispecific binding agent and to the use of such bispecific binding agents for treating leukemia, preferably, AML.
Resumen de: US2025134996A1
This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.
Resumen de: US2024117435A1
Systems and methods for predicting survival outcomes in patients diagnosed with Myelodysplastic Syndrome (MDS) are disclosed. One method may include: receiving DNA sequencing data derived from a methylation assay performed on a biological sample associated with the at least one patient; computing methylation beta-values for one or more CpG-sites identified in the sequencing data; identifying one or more differentially methylated regions (DMRs) based on statistical analysis of the methylation beta-values for the one or more CpG-sites; selecting, via a feature selection process, a subset of the one or more DMRs to utilize as training data; and training, using the training data, the classifier to predict the survival outcome of the at least one patient. Other aspects are described and claimed.
Resumen de: WO2025086418A1
A pharmaceutical composition comprising i) a recombinant fusion protein that comprises a mutated SIRPαD1 and a functional IgG1 heavy chain constant region, and ii) azacitidine, for use in treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof.
Resumen de: WO2025089328A1
The purpose of the present invention is to provide a novel non-replicating bovine infectious lymphoma virus (BLV) vaccine. The present invention provides a bovine infectious lymphoma virus (BLV) vaccine in which at least part of the function of the pol gene is deficient. The present invention also provides a method for producing a BLV vaccine, the method including a step for culturing cells that produce non-replicating bovine infectious lymphoma virus (BLV), wherein the non-replicating-BLV-producing cells contain genes of the bovine infectious lymphoma virus (BLV) in which at least a part of the function of the pol gene is deficient. The present invention is advantageous in making it possible to provide a BLV vaccine having high immunogenicity and high safety such that replication does not occur in an infected subject.
Resumen de: WO2025088367A1
The present invention relates to liposomal composition of Idarubicin and Cytarabine. The present invention also relates to liposomal composition of Idarubicin and Cytarabine comprising one or more excipients, wherein the first drug Idarubicin to second drug could Cytarabine (Ara-C) molar drug ratio is 1:17. The present invention also relates to a process for the preparation of liposomal composition of Idarubicin and Cytarabine. The present invention also relates to liposomal composition of Idarubicin and Cytarabine which shows synergistic action against acute myeloid leukemia (AML).
Resumen de: WO2025087401A1
A fused ring compound, a preparation method therefor, and use thereof. The fused ring compound has a structure represented by the formula M'-L-E-D. The compound can be used for preparing a conjugate, and the conjugate has an excellent targeted-killing effect on solid tumors, such as gastric cancer, breast cancer, lung cancer, and lymphoma, or hematologic tumors.
Resumen de: WO2025087365A1
Disclosed in the present invention are a METTL3 inhibitor as shown in general formula (I), a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the preparation of a drug for preventing and/or treating indications related to METTL3. The compound of the present invention is an ideal high-activity METTL3 inhibitor, and can be used for treating and/or preventing diseases, including AML, myeloid leukemia, and solid tumors such as hepatocellular carcinoma, colorectal cancer and prostate cancer.
Resumen de: WO2025087208A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Resumen de: US2025136998A1
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Resumen de: US2025134997A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: EP4545085A1
The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.
Resumen de: AU2023286618A1
The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.
Resumen de: US2025129435A1
The present disclosure provides a novel method of diagnosing lymphoma, breast cancer, a lymphoma subtype, or a breast cancer subtype in a patient, and kits for implementing the methods.
Resumen de: WO2025085878A1
The present invention relates to compounds of formula (A) as DUX4 inhibitors for the treatment of e.g. neuromuscular disorders, inflammatory disorders, facioscapulohumeral muscular dystrophy, B-cell leukemia, sarcomas, solid cancers, rheumatoid arthritis, axial spondylarthritis, viral infections, mononucleosis, encephalitis, and varicella. Exemplary compounds are e.g.
Resumen de: US2025129162A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Nº publicación: US2025127755A1 24/04/2025
Solicitante:
THE SCRIPPS RES INSTITUTE [US]
THE SCRIPPS RESEARCH INSTITUTE
Resumen de: US2025127755A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and hi slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
BOPI
Sede Electrónica
